Endothelial progenitor cell research in stroke - A potential shift in pathophysiological and therapeutical concepts
Endothelial progenitor cell research in stroke - A potential shift in pathophysiological and therapeutical concepts
复制标题
DOI：
10.1161/strokeaha.107.507251
复制
发表时间：
2008-07-01
期刊：
影响因子：
8.3
通讯作者：
Lodder, Jan
中科院分区：
文献类型：
--
作者：
Rouhl, Rob P. W.;van Oostenbrugge, Robert J.;Lodder, Jan
背景和目的-卒中是西方世界导致残疾的主要原因；然而，手头上几乎没有治疗方法来减轻这一负担。综述-血管内皮祖细胞(EPC)已作为因子引入心血管医学。内皮祖细胞可以修复受损的内皮细胞，延缓动脉粥样硬化的发生和发展。此外，内皮祖细胞可以在缺血区形成新的血管，从而促进缺血事件后的恢复。然而，在中风中，EPC的研究是有限的。在我们的综述中，我们提供了EPC作为一种风险标记物和潜在的治疗药物的背景信息。结论-在我们看来，EPC在中风中的研究的缺乏应该鼓励血管神经学家参与EPC的研究，因为EPC也可以改变病理生理学概念，改善血管神经学的临床治疗。
Background and Purpose - Stroke is the leading cause of disability in the Western world; however, few therapies are at hand to decrease this burden.Summary of Review - Endothelial progenitor cells (EPCs) have been introduced in cardiovascular medicine as factotums. EPCs can repair damaged endothelium and attenuate the development and progression of atherosclerosis. Also, EPCs can form new vessels in ischemic areas and thus promote recovery after ischemic events. In stroke, however, EPC research is limited. In our overview, we provide background information on EPC use as a risk marker and as a potential therapeutic agent.Conclusion - In our opinion, the lack of EPC studies in stroke should instigate vascular neurologists to participate in EPC research, as EPCs could also change pathophysiological concepts and improve clinical treatments in vascular neurology.